がん治療法の世界市場:用途別、人気商品別

◆英語タイトル:Cancer Therapeutics Market by Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Glioblastoma, Malignant Meningioma, Mesothelioma, Melanoma, and Others) and Top Selling Drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026
◆商品コード:AMR9NV072
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2019年7月
◆ページ数:261
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥579,960見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥696,600見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥971,460見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、がん治療法の世界市場について調査・分析し、市場概要、用途別(血液がん、肺がん、大腸がん、前立腺がん、乳がん、子宮頸がん、頭頸部がん、膠芽腫、悪性髄膜腫、中皮腫、黒色腫など)分析、売れ筋医薬品別(レブリミド、アバスチン、ハーセプチン、リツキサン、オプジーボ、グリベック、ベルケード、インブルビカ、イブランス、ジチガ、アリムタ、クタンディ、タルセバ、ペルジェタ、テモダールなど)分析、地域別分析、企業動向など含め、以下の構成でお届け致します。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・がん治療法の世界市場:用途別(血液がん、肺がん、大腸がん、前立腺がん、乳がん、子宮頸がん、頭頸部がん、膠芽腫、悪性髄膜腫、中皮腫、黒色腫など)
・がん治療法の世界市場:売れ筋医薬品別(レブリミド、アバスチン、ハーセプチン、リツキサン、オプジーボ、グリベック、ベルケード、インブルビカ、イブランス、ジチガ、アリムタ、クタンディ、タルセバ、ペルジェタ、テモダールなど)
・がん治療法の世界市場:地域別
・企業動向

【レポートの概要】

The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026.

Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.

However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.

The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market.
• Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry.
• An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS
• By Application
o Blood Cancer
o Lung Cancer
o Colorectal Cancer
o Prostate Cancer
o Breast Cancer
o Cervical Cancer
o Head and Neck Cancer
o Glioblastoma
o Malignant Meningioma
o Mesothelioma
o Melanoma
o Others
• By Top Selling Drugs
o Revlimid
o Avastin
o Herceptin
o Rituxan
o Opdivo
o Gleevec
o Velcade
o Imbruvica
o Ibrance
o Zytiga
o Alimta
o Xtandi
o Tarceva
o Perjeta
o Temodar
o Others
• By Region
o North America
 U.S.
 Canada
o Europe
 Germany
 France
 UK
 Italy
 Spain
 Rest of Europe
o Asia-Pacific
 Japan
 China
 India
 Australia
 South Korea
 Taiwan
 Rest of Asia-Pacific
o LAMEA
 Latin America
 Middle-East
 Africa
The list of key players operating in this market include:
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• AbbVie, Inc.
• Johnson & Johnson
• Celgene Corporation
• Astellas Pharma, Inc.
• Pfizer, Inc.
• Novartis AG
• Merck KGaA
• Eli Lilly and Company
The other players included in the value chain analysis (and not included in the report) include:
• AstraZeneca plc
• Bayer AG
• Takeda Pharmaceutical Company Limited

【レポートの目次】

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Market share analysis, 2018
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in prevalence of cancer
3.6.1.2. Surge in cancer research
3.6.1.3. Rise in strategic acquisitions & collaborations

3.6.2. Restraints

3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Adverse effects associated with cancer drug therapy

3.6.3. Opportunities

3.6.3.1. High potential associated with personalized medicines
3.6.3.2. Increase in purchasing power of emerging economies

CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Blood cancer

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Lung cancer

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Breast cancer

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Colorectal cancer

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Prostate cancer

4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Cervical cancer

4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

4.8. Head & neck cancer

4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country

4.9. Glioblastoma

4.9.1. Key market trends, growth factors, and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country

4.10. Malignant meningioma

4.10.1. Key market trends, growth factors, and opportunities
4.10.2. Market size and forecast, by region
4.10.3. Market analysis, by country

4.11. Mesothelioma

4.11.1. Key market trends, growth factors, and opportunities
4.11.2. Market size and forecast, by region
4.11.3. Market analysis, by country

4.12. Melanoma

4.12.1. Key market trends, growth factors, and opportunities
4.12.2. Market size and forecast, by region
4.12.3. Market analysis, by country

4.13. Others

4.13.1. Key market trends, growth factors, and opportunities
4.13.2. Market size and forecast, by region
4.13.3. Market analysis, by country

CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS

5.1. Overview

5.1.1. Market size and forecast

5.2. Revlimid

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by region

5.3. Avastin

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by region

5.4. Herceptin

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by region

5.5. Rituxan

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by region

5.6. Opdivo

5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by region

5.7. Gleevec

5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by region

5.8. Velcade

5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by region

5.9. Imbruvica

5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by region

5.10. Ibrance

5.10.1. Market size and forecast, by region
5.10.2. Market analysis, by region

5.11. Zytiga

5.11.1. Market size and forecast, by region
5.11.2. Market analysis, by region

5.12. Alimta

5.12.1. Market size and forecast, by region
5.12.2. Market analysis, by region

5.13. Xtandi

5.13.1. Market size and forecast, by region
5.13.2. Market analysis, by region

5.14. Tarceva

5.14.1. Market size and forecast, by region
5.14.2. Market analysis, by region

5.15. Perjeta

5.15.1. Market size and forecast, by region
5.15.2. Market analysis, by region

5.16. Temodar

5.16.1. Market size and forecast, by region
5.16.2. Market analysis, by region

5.17. Other drugs

5.17.1. Market size and forecast, by region
5.17.2. Market analysis, by region

CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. market size and forecast, by application

6.2.2.2. Canada

6.2.2.2.1. Canada market size and forecast, by application

6.2.3. North America market size and forecast, by application
6.2.4. North America market size and forecast, by top selling drugs

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe cancer therapeutics market, by country

6.3.2.1. Germany

6.3.2.1.1. Germany market size and forecast, by application

6.3.2.2. France

6.3.2.2.1. France market size and forecast, by application

6.3.2.3. UK

6.3.2.3.1. UK market size and forecast, by application

6.3.2.4. Italy

6.3.2.4.1. Italy market size and forecast, by application

6.3.2.5. Spain

6.3.2.5.1. Spain market size and forecast, by application

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe market size and forecast, by application

6.3.3. Europe market size and forecast, by application
6.3.4. Europe market size and forecast, by top selling drugs

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan market size and forecast, by application

6.4.2.2. China

6.4.2.2.1. China market size and forecast, by application

6.4.2.3. India

6.4.2.3.1. India market size and forecast, by application

6.4.2.4. Taiwan

6.4.2.4.1. Taiwan market size and forecast, by application

6.4.2.5. South Korea

6.4.2.5.1. South Korea market size and forecast, by application

6.4.2.6. Australia

6.4.2.6.1. Australia market size and forecast, by application

6.4.2.7. Rest of Asia-Pacific

6.4.2.7.1. Rest of Asia-Pacific market size and forecast, by application

6.4.3. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by top selling drugs

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Latin America

6.5.2.1.1. Latin America market size and forecast, by application

6.5.2.2. Middle East

6.5.2.2.1. Middle East market size and forecast, by application

6.5.2.3. Africa

6.5.2.3.1. Africa market size and forecast, by application

6.5.3. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by top selling drugs

CHAPTER 7: COMPANY PROFILES

7.1. AbbVie Inc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. Astellas Pharma Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. Bristol Myers Squibb Company

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. Celgene Corporation

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. Eli Lilly and Company

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. F. Hoffmann-La Roche Ltd.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. EleInformatiBusiness performance
7.6.6. Key strategic moves and developments

7.7. Johnson & Johnson

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. Merck & Co., Inc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. Novartis AG

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. Pfizer Inc.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 01. COMPLETED CLINICAL TRIALS IN CANCER THERAPEUTICS MARKET
TABLE 02. GLOBAL CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 03. BLOOD CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. BREAST CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. COLORECTAL CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. PROSTATE CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. CERVICAL CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. HEAD & NECK CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 10. GLIOBLASTOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 11. MALIGNANT MENINGIOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 12. MESOTHELIOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 13. MELANOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 14. OTHER CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 15. GLOBAL CANCER THERAPEUTICS MARKET REVENUE, BY TOP SELLING DRUGS, 2018–2026 ($MILLION)
TABLE 16. REVLIMID CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 17. AVASTIN CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 18. HERCEPTIN CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 19. RITUXAN CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 20. OPDIVO CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 21. GLEEVEC CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 22. VELCADE CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 23. IMBRUVICA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 24. IBRANCE CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 25. ZYTIGA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 26. ALIMTA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 27. XTANDI CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 28. TARCEVA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 29. PERJETA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 30. TEMODAR CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 31. CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, BY REGION, 2018–2026 ($MILLION)
TABLE 32. CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 33. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 34. U.S. CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 35. CANADA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 36. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 37. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 38. EUROPE CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 39. GERMANY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 40. FRANCE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 41. UK CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 42. ITALY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 43. SPAIN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 44. REST OF EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 45. EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 46. EUROPE CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 47. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 48. JAPAN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 49. CHINA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 50. INDIA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 51. TAIWAN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 52. SOUTH KOREA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 53. AUSTRALIA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 54. REST OF ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 55. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 56. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 57. LAMEA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 58. LATIN AMERICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 59. MIDDLE EAST CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 60. AFRICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 61. LAMEA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 62. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 63. ABBVIE: COMPANY SNAPSHOT
TABLE 64. ABBVIE: OPERATING SEGMENTS
TABLE 65. ABBVIE: PRODUCT PORTFOLIO
TABLE 66. ASTELLAS: COMPANY SNAPSHOT
TABLE 67. ASTELLAS: PRODUCT PORTFOLIO
TABLE 68. BMS: COMPANY SNAPSHOT
TABLE 69. BMS: OPERATING SEGMENTS
TABLE 70. BMS: PRODUCT PORTFOLIO
TABLE 71. CELGENE: COMPANY SNAPSHOT
TABLE 72. CELGENE: OPERATING SEGMENTS
TABLE 73. CELGENE: PRODUCT PORTFOLIO
TABLE 74. ELI LILLY: COMPANY SNAPSHOT
TABLE 75. ELI LILLY: OPERATING SEGMENTS
TABLE 76. ROCHE: COMPANY SNAPSHOT
TABLE 77. ROCHE: OPERATING SEGMENTS
TABLE 78. ROCHE: PRODUCT PORTFOLIO
TABLE 79. J&J: COMPANY SNAPSHOT
TABLE 80. J&J: OPERATING SEGMENTS
TABLE 81. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 82. MERCK: COMPANY SNAPSHOT
TABLE 83. MERCK: OPERATING SEGMENTS
TABLE 84. MERCK: PRODUCT TYPE PORTFOLIO
TABLE 85. NOVARTIS: COMPANY SNAPSHOT
TABLE 86. NOVARTIS: OPERATING SEGMENTS
TABLE 87. NOVARTIS: PRODUCT PORTFOLIO
TABLE 88. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
TABLE 89. PFIZER: COMPANY SNAPSHOT
TABLE 90. PFIZER: OPERATING SEGMENTS
TABLE 91. PFIZER: PRODUCT PORTFOLIO

【レポートのキーワード】

がん治療法、血液がん、肺がん、大腸がん、前立腺がん、乳がん、子宮頸がん、頭頸部がん、膠芽腫、悪性髄膜腫、中皮腫、黒色腫、レブリミド、アバスチン、ハーセプチン、リツキサン、オプジーボ、グリベック、ベルケード、インブルビカ、イブランス、ジチガ、アリムタ、クタンディ、タルセバ、ペルジェタ、テモダール

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[がん治療法の世界市場:用途別、人気商品別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆